The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer

Oncogene

Volumn 33, Issue 30, 2014, Pages 3980-3991

  Witkiewicz, A K ^a,b   Cox, D W ^a   Rivadeneira, D ^c   Ertel, A E ^c   Fortina, P ^c   Schwartz, G F ^c   Knudsen, E S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CYCLIN A; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MINICHROMOSOME MAINTENANCE PROTEIN 7; PALBOCICLIB; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST EPITHELIUM; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CELL ADHESION; CELL PROLIFERATION; DEREGULATION; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTRADUCTAL CARCINOMA; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE, TUMOR; CELL POLARITY; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; RECEPTOR, ERBB-2; RETINOBLASTOMA PROTEIN; RISK; TRANSCRIPTOME;

EID: 84905037705     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.367     Document Type: Article

References (56)

1. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002; 94: 1546-1554 (Pubitemid 35277278)
2. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: A systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010; 102: 170-178
3. Betsill Jr WL, Rosen PP, Lieberman PH, Robbins GF. Intraductal carcinoma. Longterm follow-up after treatment by biopsy alone. Jama 1978; 239: 1863-1867 (Pubitemid 8322874)
4. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009; 7: 122-192
5. Schnitt SJ. Local outcomes in Ductal carcinoma in situ based on patient and tumor characteristics. J Natl Cancer Inst Monogr 2010; 41: 158-161
6. Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S et al. National Institutes of Health State-of-The-Science Conference statement: Diagnosis and management of ductal carcinoma in situ September 22-24, 2009. J Natl Cancer Inst 2010; 102: 161-169
7. Jones JL. Overdiagnosis and overtreatment of breast cancer: Progression of ductal carcinoma in situ: The pathological perspective. Breast Cancer Res 2006; 8: 204
8. Romero L, Klein L, Ye W, Holmes D, Soni R, Silberman H et al. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. Am J Surg 2004; 188: 371-376 (Pubitemid 39330538)
9. Kerlikowske K, Molinaro A, Cha I, Ljung BM, Ernster VL, Stewart K et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 2003; 95: 1692-1702 (Pubitemid 37509078)
10. Knudsen ES, Ertel A, Davicioni E, Kline J, Schwartz GF, Witkiewicz AK. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat 2011; 133: 1009-1024
11. Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, Colditz G et al. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res 2012; 72: 4574-4586
12. Franke WW. Discovering the molecular components of intercellular junctions-A historical view. Cold Spring Harb Perspect Biol 2009; 1: A003061
13. Zhurinsky J, Shtutman M, Ben-Zeev A. Plakoglobin and beta-catenin: Protein interactions, regulation and biological roles. J Cell Sci 2000; 113(Pt 18): 3127-3139
14. Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 2003; 19: 207-235 (Pubitemid 37487348)
15. Rodriguez-Boulan E, Nelson WJ. Morphogenesis of the polarized epithelial cell phenotype. Science 1989; 245: 718-725 (Pubitemid 19214003)
16. O"Brien LE, Zegers MM, Mostov KE. Opinion: Building epithelial architecture: Insights from three-dimensional culture models. Nat Rev Mol Cell Biol 2002; 3: 531-537 (Pubitemid 34733434)
17. Kim YS, Won YS, Park KS, Song BJ, Kim JS, Oh SJ et al. Prognostic significance of HER2 gene amplification according to stage of breast cancer. J Korean Med Sci 2008; 23: 414-420
18. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-368
19. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182 (Pubitemid 17231334)
20. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992; 23: 974-979
21. Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN et al. Her-2/ neu gene amplification in Ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2002; 11: 587-590 (Pubitemid 34615167)
22. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS. ErbB2 but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 2001; 3: 785-792 (Pubitemid 32842683)
23. Wu M, Jung L, Cooper AB, Fleet C, Chen L, Breault L et al. Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. Proc Natl Acad Sci USA 2009; 106: 7022-7027
24. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010; 102: 627-637
25. Gauthier ML, Berman HK, Miller C, Kozakeiwicz K, Chew K, Moore D et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 2007; 12: 479-491 (Pubitemid 350046408)
26. Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF et al. Association of RB/p16-pathway perturbations with DCIS recurrence dependence on tumor versus tissue microenvironment. Am J Pathol 2010; 179: 1171-1178
27. Knudsen ES, Pajak TF, Qeenan M, McClendon AK, Armon BD, Schwartz GF et al. Retinoblastoma and phosphate and tensin homolog tumor suppressors: Impact on Ductal carcinoma in situ progression. J Natl Cancer Inst 2012; 104: 1825-1836
28. Knudsen ES, Knudsen KE. Tailoring to RB: Tumour suppressor status and therapeutic response. Nat Rev Cancer 2008; 8: 714-724
29. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 2005; 24: 2796-2809 (Pubitemid 40638091)
30. Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC et al. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest 2010; 120: 3296-3309
31. Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 2008; 10: R75
32. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-268 (Pubitemid 36677560)
33. Hebner C, Weaver VM, Debnath J. Modeling morphogenesis and oncogenesis in three-dimensional breast epithelial cultures. Annu Rev Pathol 2008; 3: 313-339 (Pubitemid 351488284)
34. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007; 1: 84-96 (Pubitemid 46776616)
35. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J et al. Core epithelial-To-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 2010; 107: 15449-15454
36. Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 1992; 89: 9064-9068.
37. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005; 48: 2388-2406 (Pubitemid 40516432)
38. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3: 1427-1438
39. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: Key mechanisms of response and failure. Oncogene 2010; 29: 4018-4032
40. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001; 61: 5168-5178 (Pubitemid 32681550)
41. Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breastconserving therapy for ductal carcinoma in situ. Br J Cancer 2012; 106: 1160-1165
42. Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C et al. Overview of the randomized trials of radiotherapy in Ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010; 41: 162-177
43. Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: A review. Breast Cancer Res Treat 2006; 97: 135-144
44. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004; 96: 906-920 (Pubitemid 38868137)
45. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2012; 144: 646-674
46. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004; 4: 118-132 (Pubitemid 38198740)
47. Knudsen ES, Ertel A, Davicioni E, Kline J, Schwartz GF, Witkiewicz AK. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat 2011; 133: 1009-12422.
48. Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004; 9: 95-104 (Pubitemid 39137499)
49. Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Grana X et al. Proliferative suppression by CDK4/6 inhibition: Complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology 2010; 138: 1920-1930
50. Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK et al. Therapeutically activating RB: Reestablishing cell cycle control in endocrine therapyresistant breast cancer. Endocr Relat Cancer 2011; 18: 333-345
51. Knudsen ES, Buckmaster C, Chen TT, Feramisco JR, Wang JY. Inhibition of DNA synthesis by RB: Effects on G1/S transition and S-phase progression. Genes Dev 1998; 12: 2278-2292 (Pubitemid 28371349)
52. Sotgia F, Williams TM, Schubert W, Medina F, Minetti C, Pestell RG et al. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol 2006; 168: 292-309 (Pubitemid 43062581)
53. Storey JD. A direct approach to false discovery rates. J R Stat Soc 2002; 64: 479-498
54. Hackstadt AJ, Hess AM. Filtering for increased power for microarray data analysis. BMC Bioinformatics 2009; 10: 11
55. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550 (Pubitemid 41528093)
56. McClendon AK, Dean JL, Ertel A, Fu Z, Rivadeneira DB, Reed CA et al. RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. Gastroenterology 2011; 141: 1439-1450.